文献速递乳腺癌放疗放疗物理与技术

CD44与MAT1A基因变异增加乳腺癌放疗急性皮肤反应易感性

Genetic Variants in CD44 and MAT1A Confer Susceptibility to Acute Skin Reaction in Breast Cancer Patients Undergoing Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2016-09-20

研究在乳腺癌放疗患者中检测18个放射反应基因的22个变异,发现CD44的rs8193多态性与急性皮肤不良反应显著相关(P=.0270),MAT1A与CD44存在基因-基因交互作用(P=.0107),且风险等位基因总数增加与过度反应发生率升高相关(P=.0302)。

要点

  • CD44的rs8193多态性与放疗急性皮肤反应显著相关(P=.0270)。
  • MAT1A与CD44存在显著基因-基因交互作用(P=.0107)。
  • 风险等位基因总数增加与过度反应发生率升高相关(P=.0302)。

核心结论

  • 放射反应基因的遗传多态性通过单基因效应、基因-基因交互作用和/或风险等位基因的累加效应修饰放疗后急性正常组织毒性结局。

研究设计与样本

  • 在乳腺癌患者队列中,采用TaqMan实时聚合酶链反应检测18个基因(NFE2L2、OGG1、NEIL3、RAD17、PTTG1、REV3L、ALAD、CD44、RAD9A、TGFβR3、MAD2L2、MAP3K7、MAT1A、RPS6KB2、ZNF830、SH3GL1、BAX、XRCC1)的22个遗传变异。
  • 放疗结束时按放射治疗肿瘤学组(RTOG)标准评分皮肤损伤严重程度,将受试者分为非过度反应者(RTOG分级<2)和过度反应者(RTOG分级≥2)进行分析。

主要发现

  • 在22个单核苷酸多态性中,位于CD44 3'-UTR微小RNA结合位点的rs8193多态性与放疗诱导的不良皮肤反应显著相关(P=.0270)。
  • 广义多因子降维分析显示MAT1A与CD44之间存在显著的基因-基因交互作用(P=.0107)。
  • 风险等位基因总数增加与过度反应发生率升高相关(P=.0302)。

临床怎么用

  • CD44 rs8193、MAT1A-CD44交互作用及风险等位基因负荷可能作为预测放疗急性皮肤反应的生物标志物。

局限性

  • 研究为乳腺癌患者队列,结论外推至其他瘤种需谨慎。
  • 样本量及具体人群特征未在摘要中报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Heterogeneity in radiation therapy (RT)-induced normal tissue toxicity is observed in 10% of cancer patients, limiting the therapeutic outcomes. In addition to treatment-related factors, normal tissue adverse reactions also manifest from genetic alterations in distinct pathways majorly involving DNA damage-repair genes, inflammatory cytokine genes, cell cycle regulation, and antioxidant response. Therefore, the common sequence variants in these radioresponsive genes might modify the severity of normal tissue toxicity, and the identification of the same could have clinical relevance as a predictive biomarker. METHODS AND MATERIALS: The present study was conducted in a cohort of patients with breast cancer to evaluate the possible associations between genetic variants in radioresponsive genes described previously and the risk of developing RT-induced acute skin adverse reactions. We tested 22 genetic variants reported in 18 genes (ie, NFE2L2, OGG1, NEIL3, RAD17, PTTG1, REV3L, ALAD, CD44, RAD9A, TGFβR3, MAD2L2, MAP3K7, MAT1A, RPS6KB2, ZNF830, SH3GL1, BAX, and XRCC1) using TaqMan assay-based real-time polymerase chain reaction. At the end of RT, the severity of skin damage was scored, and the subjects were dichotomized as nonoverresponders (Radiation Therapy Oncology Group grade <2) and overresponders (Radiation Therapy Oncology Group grade ≥2) for analysis. RESULTS: Of the 22 single nucleotide polymorphisms studied, the rs8193 polymorphism lying in the micro-RNA binding site of 3'-UTR of CD44 was significantly (P=.0270) associated with RT-induced adverse skin reactions. Generalized multifactor dimensionality reduction analysis showed significant (P=.0107) gene-gene interactions between MAT1A and CD44. Furthermore, an increase in the total number of risk alleles was associated with increasing occurrence of overresponses (P=.0302). CONCLUSIONS: The genetic polymorphisms in radioresponsive genes act as genetic modifiers of acute normal tissue toxicity outcomes after RT by acting individually (rs8193), by gene-gene interactions (MAT1A and CD44), and/or by the additive effects of risk alleles.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Mumbrekar KD, Bola Sadashiva SR, Kabekkodu SP, et al. Genetic Variants in CD44 and MAT1A Confer Susceptibility to Acute Skin Reaction in Breast Cancer Patients Undergoing Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016. PMID: 27816361. doi:10.1016/j.ijrobp.2016.09.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。